Eteplirsen

Drug Profile

Eteplirsen

Alternative Names: AVI 4658; AVI-4658 PMO; Exondys 51

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator AVI BioPharma; Ercole Biotech
  • Developer Sarepta Therapeutics
  • Class Antisense oligonucleotides; Morpholines
  • Mechanism of Action Dystrophin expression modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Registered Duchenne muscular dystrophy

Most Recent Events

  • 28 Feb 2017 Sarepta Therapeutics has patent protection for Eteplirsen in USA and EU (Sarepta therapeutics Form 10-K, March 2017)
  • 21 Feb 2017 Sarepta Therapeutics enters into an agreement to sell its Rare Paediatric Disease Priority Review Voucher
  • 19 Dec 2016 Preregistration for Duchenne muscular dystrophy in European Union (IV) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top